A Phase 1b, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Dalantercept (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms The DASH Study
- Sponsors Acceleron Pharma
- 10 Jun 2017 Biomarkers information updated
- 22 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
- 22 Nov 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Jun 2017.